prior
ebola
outbreak
data
ebola
vaccin
deriv
nonclin
efficaci
studi
small
anim
nonhuman
primat
clinic
evalu
limit
respons
west
africa
ebola
outbreak
acceler
clinic
evalu
develop
sever
ebola
vaccin
candid
two
lead
candid
fund
janssen
vaccin
prevent
bv
primeboost
vaccin
also
receiv
fund
niaid
near
consider
licensur
vaccin
produc
rapid
immun
respons
sustain
one
year
post
vaccin
merck
pursu
fda
licensur
tradit
approv
pathway
emphas
clinic
efficaci
data
gener
ring
vaccin
studi
conduct
guinea
primeboost
vaccin
safe
well
toler
produc
sustain
immun
respons
one
year
post
vaccin
janssen
vaccin
prevent
bv
pursu
fda
licensur
anim
ruleacceler
pathway
requir
demonstr
clinic
efficaci
establish
immun
correl
within
nonhuman
primat
anim
model
primeboost
vaccin
candid
evalu
multipl
phase
ii
iii
clinic
trial
zmapp
investig
drug
develop
mapp
biopharmaceut
cocktail
compos
chimer
monoclon
antibodi
mab
target
ebola
viru
glycoprotein
ebovgp
efficaci
zmapp
assess
prevail
ii
phase
iii
clinic
trial
guinea
liberia
sierra
leon
us
outbreak
although
predetermin
statist
threshold
success
met
due
limit
enrol
final
month
outbreak
trend
toward
efficaci
evid
zmapp
wide
consid
compon
standard
care
part
respons
march
ebola
flareup
origin
prefectur
guinea
spread
liberia
zmapp
drug
also
avail
use
may
outbreak
democrat
republ
congo
mapp
biopharmaceut
barda
fda
partner
make
zmapp
avail
us
liberia
sierra
leon
guinea
expand
access
protocol
ensur
continu
avail
patient
ebola
viru
diseas
fulli
human
cocktail
develop
regeneron
outbreak
target
ebovgp
current
evalu
phase
clinic
studi
barda
collabor
regeneron
sinc
provid
fund
nonclin
studi
manufactur
phase
studi
expect
bolster
usg
capabl
deploy
immunotherapeut
event
public
health
emerg
declar
end
west
africa
ebola
epidem
june
outbreak
democrat
republ
congo
remind
ebola
viru
remain
secur
health
threat
outbreak
highlight
need
improv
way
incentiv
industri
coordin
domest
intern
respons
make
necessari
vaccin
diagnost
therapeut
effect
respond
emerg
neglect
tropic
diseas
threat
biothreat
may
commerci
market
usg
advanc
develop
organ
medic
countermeasur
barda
posit
contribut
larger
global
r
blue
print
http
wwwwhointblueprintabouten
effort
center
epidem
prepared
innov
cepi
address
emerg
neglect
tropic
diseas
outbreak
intern
concern
aris
coordin
organ
well
intern
stakehold
critic
ensur
appropri
resourc
expertis
brought
bear
futur
outbreak
order
rapidli
respond
novel
threat
emphasi
platform
capabl
rapidli
screen
identifi
manufactur
vaccin
therapeut
candid
need
end
barda
continu
assess
evalu
potenti
platform
technolog
part
larger
portfolio
product
includ
effort
develop
medic
countermeasur
emerg
infecti
diseas
middl
east
respiratori
syndrom
mer
zika
number
challeng
must
overcom
ensur
adequ
prepared
futur
ebola
outbreak
includ
complet
remain
advanc
develop
activ
necessari
regulatori
approv
subsequ
stockpil
medic
countermeasur
use
public
health
emerg
barda
remain
commit
make
avail
safe
effect
fdaapprov
vaccin
therapeut
ebola
public
health
emerg
despit
advanc
aforement
vaccin
therapeut
ebola
gap
remain
overal
prepared
postur
filovirus
barda
pursu
develop
vaccin
therapeut
sudan
ebolaviru
marburg
viru
address
gap
acknowledg
much
work
remain
prepar
futur
filoviru
outbreak
recent
announc
barda
award
vaccin
therapeut
ebola
repres
import
mileston
prepared
ongo
commit
counter
health
secur
threat
